Answers are grounded in this paper and cite their sources.
Evaluates zirconium-89's ability to predict actinium-225 tumour dose in renal cancer models, indicating potential for improved dosimetry.
The aim of this study was to assess whether zirconium-89 ( 89 Zr)-labelled antibodies can act as a surrogate for actinium-225 ( 225 Ac)-labelled antibodies to predict tumour- and organ dose. To this end, we performed ex vivo biodistribution and dosimetry studies with two anti-CAIX antibodies (hG250 and FcRn(-)hG250), radiolabelled with 89 Zr and 225 Ac, in a renal cell carcinoma mouse model. Methods BALB/c nude mice bearing subcutaneous SK-RC-52 tumours were injected intravenously with 25–50 kBq 225 Ac-labelled or 1 MBq 89 Zr-labelled anti-CAIX antibody, at equal protein dose. Organ and tumour absorbed doses were calculated based on the uptake data at 4, 24, 72, and 168 h for FcRn(-)hG250 and 24, 72, and 168 h for hG250. The predictive value of 89 Zr for 225 Ac was evaluated in both groups, by comparing the predicted 225 Ac absorbed dose (based on 89 Zr-antibody) and the measured 225 Ac absorbed dose. Results The biodistribution profile of the theranostic pair 89 Zr/ 225 Ac was comparable for FcRn(-)hG250. For hG250, significant discrepancies between tumour, spleen and liver uptake were observed. The predicted 225 Ac tumour dose was overestimated by 3.9 ± 2.0 Gy (6 ± 50.6%) and underestimated by 1413.7 ± 629.1 Gy (69 ± 44.5%) in the FcRn(-)hG250 and hG250 groups, respectively. The deviation of the predicted versus measured 225 Ac-dose in off-target organs was most notable in liver and spleen for both antibodies. Conclusion This study highlights variability in the predictive accuracy of the 89 Zr/ 225 Ac theranostic pair for tumour and organ dosimetry in a ccRCC mouse model, depending on the antibody used. FcRn(-)hG250 enabled accurate tumour dose estimation, whereas hG250 showed mismatched uptake limiting prediction, possibly due to inherent differences in the properties and biological effects of both 225 Ac and 89 Zr. These findings underscore the need to further investigate how 89 Zr-PET can be used for 225 Ac-TRT dose prediction.
No takes yet. Share an insight, caveat, or question.
Merkx et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: